Numeric Investors LLC cut its stake in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 95.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 45,300 shares of the biotechnology company’s stock after selling 892,185 shares during the period. Numeric Investors LLC owned 0.06% of Momenta Pharmaceuticals worth $766,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Tortoise Investment Management LLC purchased a new stake in shares of Momenta Pharmaceuticals during the 2nd quarter valued at $114,000. Pinebridge Investments L.P. grew its stake in shares of Momenta Pharmaceuticals by 4.3% during the 2nd quarter. Pinebridge Investments L.P. now owns 8,798 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 363 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Momenta Pharmaceuticals during the 1st quarter valued at $158,000. BNP Paribas Arbitrage SA grew its stake in shares of Momenta Pharmaceuticals by 13.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 13,393 shares of the biotechnology company’s stock valued at $179,000 after buying an additional 1,570 shares during the period. Finally, Envestnet Asset Management Inc. grew its stake in shares of Momenta Pharmaceuticals by 3.0% during the 1st quarter. Envestnet Asset Management Inc. now owns 14,275 shares of the biotechnology company’s stock valued at $191,000 after buying an additional 411 shares during the period. 93.88% of the stock is owned by institutional investors.
In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 4,116 shares of the firm’s stock in a transaction on Monday, August 21st. The shares were sold at an average price of $15.07, for a total value of $62,028.12. Following the sale, the president now directly owns 269,231 shares in the company, valued at approximately $4,057,311.17. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Craig A. Wheeler sold 35,667 shares of the firm’s stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $19.03, for a total transaction of $678,743.01. Following the completion of the sale, the president now owns 286,121 shares in the company, valued at $5,444,882.63. The disclosure for this sale can be found here. Insiders sold a total of 79,663 shares of company stock worth $1,414,498 over the last quarter. 4.40% of the stock is currently owned by company insiders.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) opened at 12.90 on Friday. The firm has a 50-day moving average of $16.36 and a 200-day moving average of $15.77. The stock’s market capitalization is $955.32 million. Momenta Pharmaceuticals, Inc. has a 52-week low of $10.75 and a 52-week high of $19.90.
Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.50). Momenta Pharmaceuticals had a negative net margin of 39.35% and a negative return on equity of 12.28%. The business had revenue of $23.57 million for the quarter, compared to analyst estimates of $24.64 million. During the same period last year, the business posted ($0.31) EPS. Momenta Pharmaceuticals’s revenue was down 10.8% compared to the same quarter last year. On average, equities analysts expect that Momenta Pharmaceuticals, Inc. will post ($1.50) EPS for the current year.
MNTA has been the subject of several research reports. Zacks Investment Research cut shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. BidaskClub raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Stifel Nicolaus reaffirmed a “hold” rating and set a $15.00 price target (down from $22.00) on shares of Momenta Pharmaceuticals in a research report on Wednesday, October 4th. Maxim Group set a $6.00 price target on shares of Momenta Pharmaceuticals and gave the stock a “sell” rating in a research report on Thursday, August 3rd. Finally, Goldman Sachs Group, Inc. (The) initiated coverage on shares of Momenta Pharmaceuticals in a research report on Thursday, September 28th. They set a “neutral” rating and a $18.00 price target for the company. Three equities research analysts have rated the stock with a sell rating and nine have assigned a hold rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $15.00.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.